Unknown

Dataset Information

0

Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition.


ABSTRACT: The coronaviruses responsible for severe acute respiratory syndrome (SARS-CoV), COVID-19 (SARS-CoV-2), Middle East respiratory syndrome-CoV, and other coronavirus infections express a nucleocapsid protein (N) that is essential for viral replication, transcription, and virion assembly. Phosphorylation of N from SARS-CoV by glycogen synthase kinase 3 (GSK-3) is required for its function and inhibition of GSK-3 with lithium impairs N phosphorylation, viral transcription, and replication. Here we report that the SARS-CoV-2 N protein contains GSK-3 consensus sequences and that this motif is conserved in diverse coronaviruses, raising the possibility that SARS-CoV-2 may be sensitive to GSK-3 inhibitors, including lithium. We conducted a retrospective analysis of lithium use in patients from three major health systems who were PCR-tested for SARS-CoV-2. We found that patients taking lithium have a significantly reduced risk of COVID-19 (odds ratio = 0.51 [0.35-0.74], P = 0.005). We also show that the SARS-CoV-2 N protein is phosphorylated by GSK-3. Knockout of GSK3A and GSK3B demonstrates that GSK-3 is essential for N phosphorylation. Alternative GSK-3 inhibitors block N phosphorylation and impair replication in SARS-CoV-2 infected lung epithelial cells in a cell-type-dependent manner. Targeting GSK-3 may therefore provide an approach to treat COVID-19 and future coronavirus outbreaks.

SUBMITTER: Liu X 

PROVIDER: S-EPMC8594528 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC289081 | biostudies-other
| S-EPMC8510267 | biostudies-literature
| S-EPMC7111943 | biostudies-literature
| S-EPMC4336326 | biostudies-literature
| S-EPMC7103413 | biostudies-literature
| S-EPMC7113676 | biostudies-literature
| S-EPMC7122433 | biostudies-literature
| S-EPMC7111152 | biostudies-literature
| S-EPMC2001268 | biostudies-literature
| S-EPMC7092856 | biostudies-literature